Target intelligence / Profile preview

Intracellular iron (Fe) (Fe)

Target
Fe
Molecular classification
Metal ion, Micronutrient
01

Overview

Intracellular iron, specifically the labile iron pool (LIP), represents a critical yet tightly regulated reservoir of redox-active iron ions (Fe2+ and Fe3+) within the cell. This pool serves as a source of iron for the synthesis of heme and iron-sulfur clusters, which are essential for mitochondrial respiration, DNA repair, and various enzymatic activities (Kakhlon & Cabantchik, 2002; Hentze et al., 2004). Despite its necessity, excess intracellular iron is highly toxic; it catalyzes the formation of reactive oxygen species (ROS) via the Fenton reaction, leading to oxidative stress and the induction of ferroptosis, a regulated cell death pathway (Dixon et al., 2012). In clinical settings, intracellular iron is the primary target for iron-chelating therapies used to treat systemic iron overload resulting from chronic blood transfusions or genetic disorders like hemochromatosis (Mobarra et al., 2016). Emerging research also focuses on modulating intracellular iron levels to selectively induce cell death in cancer cells or to mitigate neurodegeneration associated with iron accumulation in the brain (Dixon et al., 2012; Mobarra et al., 2016). These therapeutic strategies leverage the unique redox chemistry of iron to either protect tissues from oxidative damage or to exploit iron dependency in pathological cells.

Other names
Labile iron poolLIPCellular ironIntracellular Fe2+/Fe3+Cytosolic ironIntracellular Fe/Fe
02

Mechanism of action

Chelation of redox-active iron ions to form stable, non-toxic complexes that are excreted from the body, thereby preventing oxidative damage and reducing iron-dependent cellular processes.

03

Biological functions

Redox signalingDNA synthesisMitochondrial respirationOxygen transportFerroptosis
04

Disease associations

Iron overloadHereditary hemochromatosisThalassemiaCancerNeurodegenerative diseaseFriedreich's ataxia
05

Safety considerations

AgranulocytosisRenal toxicityHepatic impairmentOcular and auditory toxicityIron deficiency anemiaIncreased risk of infection (e.g., Yersinia enterocolitica)
06

Interacting drugs

Deferoxamine

2 more in the full profile.

07

Biomarkers

Serum ferritinTransferrin saturationLabile plasma iron (LPI)Liver iron concentration (LIC)Intracellular labile iron pool (LIP) assays

Beyond the preview

Go deeper on Intracellular iron (Fe) (Fe).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intracellular iron (Fe) (Fe).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call